Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04882046
Other study ID # 2020-072
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 23, 2021
Est. completion date December 2023

Study information

Verified date August 2022
Source Institut Pasteur
Contact Julie CAGLIERO, PhD
Phone +687 93 71 37
Email jcagliero@pasteur.nc
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to estimate the incidence of Jarisch-Herxheimer Reactions (JHR) during antibiotic treatment of human leptospirosis cases in New Caledonia. Participants are patients managed in one of the 5 centres participating in the study, in whom a clinical doctor suspected leptospirosis. The average number of leptospirosis cases in New Caledonia is 89 per year. Given the proportion of positive diagnostic tests (approximately 10%) 900 inclusions are planned for this study. Patients are included at the time of the consultation during which leptospirosis is suspected, before the initiation of their antibiotic therapy and independently of the clinical form they presented. Data (socio-demographic and health) and blood samples will be collected at 3 points in the study: at baseline, three hours and six hours after antibiotic treatment. This study will allow better management of patients with leptospirosis.


Description:

The objective of the study is to estimate the incidence of Jarisch-Herxheimer Reactions (JHR) during antibiotic treatment of human leptospirosis cases in New Caledonia. Secondary objectives of the study are to describe the JHR during leptospirosis (describe clinical, haemodynamic and cytokine response parameters), to describe the effects of the progressive introduction of antibiotic (ATB) for the treatment of leptospirosis and to harmonise management practices for patients with leptospirosis in NC. Participants are patients managed in one of the 5 centres participating in the study, in whom a clinical doctor suspected leptospirosis. The average number of leptospirosis cases in New Caledonia (NC) is 89 per year. Given the proportion of positive diagnostic tests (approximately 10%) 900 inclusions are planned for this study. Patients are included at the time of the consultation during which leptospirosis is suspected, before the initiation of their antibiotic therapy and independently of the clinical form they presented. Blood samples will be collected at 3 points in the study: at baseline, three hours and six hours after antibiotic treatment. Data will be collected at 4 points in the study: at baseline, three hours, six hours after antibiotic treatment and one day after treatment introduction (last point by phone call). The data obtained will allow us to describe for the first time, in a prospective study, the JHR associated with leptospirosis in a significant number of patients. The data obtained will also help to describe the impact of a therapeutic strategy on the evolution of the disease, which has not yet been evaluated. This study also aims to help harmonise the management of patients with leptospirosis in NC. This study will allow better management of patients with leptospirosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 900
Est. completion date December 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be over 18 years of age (at the time of inclusion); - Be suspected of developing leptospirosis by the clinician in one of the 5 participating centres - Have been informed of the use of their samples for non-therapeutic scientific research purposes by a note and information sheet established by the Institut Pasteur of New Caledonia (IPNC) and the Institut Pasteur Paris (IPP), provided and explained by the inclusion centre. - Have expressed their oral consent to participate in this research project Non inclusion criteria: - Under 18 years of age - Have not given oral consent to participate - Have a chronic inflammatory disease. - Having concomitant antibiotic and/or anti-inflammatory treatment or medical management incompatible with the purpose of the study, - Pregnant or breastfeeding women. Exclusion Criteria: - Leptospirosis diagnostic is not confirmed by molecular biology. Complete destruction of the corresponding samples will be ensured. Clinical data and biological analyses will also be removed from the data associated with the research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood collection
Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
Data collection
collection of socio-demographic, clinical and biological data.

Locations

Country Name City State
New Caledonia Centre Médico-Social Jeanne Boutin Bourail Nouvelle Calédonie
New Caledonia Centre hospitalier du Nord Koné
New Caledonia Centre hospitalier du Nord Koumac
New Caledonia Centre hospitalier Territorial Gaston-Bourret Nouméa Nouvelle Calédonie
New Caledonia Centre hospitalier du Nord Poindimié

Sponsors (1)

Lead Sponsor Collaborator
Institut Pasteur

Country where clinical trial is conducted

New Caledonia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of JHR during follow-up of patients with leptospirosis at the initiation of antibiotic therapy. The incidence of JHR will be calculated on the total number of patients included by recording the number of participants who developed or showed an aggravation of at least one of the following clinical symptoms: Fever, tremor, chills, headache, muscle stiffness and/or pain and change in the patient's haemodynamic status (blood pressure, pulse, respiratory rate, oxygen saturation). 1 year
Secondary Description of JHR during leptospirosis The description of the groups of patient with JHR will be compared to the group without JHR in terms of clinical and haemodynamic parameters Any occurrence of other unexpected clinical symptoms will be described. 1 year
Secondary Description of the administration of antibiotic treatment used for leptospirosis. The incidence of JHR will be described on a case-by-case basis according to the antibiotic treatment (type of antibiotics, dose and mode of administration) implemented by the clinician. 1 year
Secondary Description of inflammatory markers during JHR Description of markers of inflammation (inflammatory cytokines as TNF-a (tumor necrosis factors alpha), IL-1ß, IL-10, IL-8, IL-6 (interleukines) and CRP) on patients with leptospirosis 1 year
Secondary Association of markers of inflammation with the onset of JHR. Association of markers of inflammation (inflammatory cytokines as TNF-a, IL-1ß, IL-10, IL-8, IL-6 and CRP) with the apparition of JHR on patients with leptospirosis 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02898519 - Immune Response After Leptospirosis Infection N/A
Recruiting NCT05425524 - Leptospirosis Care Bundle Study N/A
Completed NCT03912506 - Severe Leptospirosis in Non-tropical Areas
Recruiting NCT04288674 - Leptospirosis Registry - LeptoScope
Recruiting NCT05300425 - Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Completed NCT01080989 - The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands N/A
Recruiting NCT05436756 - Chronic Post-leptospirosis Manifestations in Reunion N/A
Terminated NCT00592566 - Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis Phase 2/Phase 3
Recruiting NCT04034550 - Cohort of Hospitalized Patients Suspected of Leptospirosis N/A
Completed NCT05413720 - Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO N/A
Completed NCT01766830 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) N/A
Recruiting NCT02000635 - Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Active, not recruiting NCT01607047 - French West Indies Leptospirosis Study
Completed NCT03497572 - Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine